Raphael Pharmaceutical Inc. (RAPH) intrinsic value & 10-year financials
Raphael Pharmaceutical Inc. (RAPH) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.40
- Market cap
- $27.4M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- 366.8%
- ROIC (10-yr avg)
- -326.1%
- Free cash flow (FY2025)
- —
RAPH 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$1.3M | $0.07 | — | — | 177.6% |
| FY2024 | — | -$1.5M | $0.08 | — | — | 211.0% |
| FY2023 | — | -$1.3M | $0.07 | — | — | 1595.0% |
| FY2022 | $2.4M | -$3.4M | $0.23 | -$761.0K | -138.4% | -2870.1% |
| FY2021 | $195.0K | -$1.6M | $0.14 | — | -835.4% | -742.0% |
| FY2020 | $110.0K | -$718.0K | — | — | -641.8% | -327.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Raphael Pharmaceutical Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Raphael Pharmaceutical Inc. has historically struggled to out-earn its cost of capital, averaging just -3.3% ROIC.
Raphael Pharmaceutical Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Raphael Pharmaceutical Inc. is modeled at -15.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-1.41 per share.